Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11575925 | 0.86 | CYP1A2 (0.68) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29524334 | 0.85 | TPMT (0.69) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL30446783 | 0.85 | TAS1R3 (0.52) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1191273 | 0.85 | TAS1R3 (0.52) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8195142 | 0.85 | LMNA (0.55) | ADRB2SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL308170 | 0.85 | TPMT (0.69) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL16953968 | 0.84 | TAS1R3 (0.48) | ADRB2SMN1; SMN2NPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL306990 | 0.83 | CA12 (0.67) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL18761557 | 0.83 | ESRRA (0.50) | ADRB2SMN1; SMN2NPC1RAB9AMEN1 | |
| Methyl 3-Chloro-4-Methoxybenzoate SCHEMBL1637523 | 0.83 | KMT2A (0.69) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11130737-A | — | — | None | — | — | JP | disclosed |
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240327386-A1 | AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR | CHONGQING PHARSCIN INNOBIO CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-117126151-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117069713-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069712-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117024420-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-1996012697-A2 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1995021817-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0255728-B1 | PHENOXYACETIC ACID COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE | TANABE SEIYAKU CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
| EP-0191496-B1 | TRIAZINE DERIVATIVES, A PROCESS FOR PREPARING THE DERIVATIVES, AND HERBICIDES CONTAINING THE DERIVATIVES AS THE EFFECTIVE COMPONENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-10-31 | — | — | EP | disclosed |
| US-4866196-A | ANTICOAGULANTS | TANABE SEIYAKU CO., LTD. (JP) | 1989-09-12 | — | — | US | disclosed |
| CN-1004204-B | Herbicide containing triazine derivative as active ingredient | 出光兴产株式会社 | 1989-05-17 | — | — | CN | disclosed |
| EP-0255728-A2 | Phenoxyacetic acid compounds, their preparation, pharmaceutical composition and use | TANABE SEIYAKU CO., LTD. (JP) | 1988-02-10 | — | — | EP | disclosed |
| US-4680054-A | Triazine derivatives, a process for preparing the derivatives, and herbicides containing the derivatives as the effective component | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1987-07-14 | — | — | US | disclosed |
| EP-0191496-A2 | Triazine Derivatives, a process for preparing the derivatives, and herbicides containing the derivatives as the effective component | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1986-08-20 | — | — | EP | disclosed |
| CN-86100884-A | Process for preparing triazine derivatives and herbicides containing the derivatives as active ingredient | — | 1986-08-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | ADRB2 290/4885SMN1; SMN2 1/4885NPC1 278/4885 |
| US-20240327386-A1 | AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR | AHR, ARNT, AIPL1 | ADRB2 575/4885SMN1; SMN2 4850/4885NPC1 1232/4885 |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, CTSA | ADRB2 290/4885SMN1; SMN2 1/4885NPC1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.